Related news and resources
Joint Note for Guidance on social media and digital channels
In a new Note for Guidance, IFPMA and EFPIA provide non-binding advice for their members when considering their activities on social media and digital channels. The document seeks to support and guide pharmaceutical companies and associations and anyone acting on their behalf in always basing their cooperation with Healthcare Professionals (HCPs), Healthcare Organizations (HCOs), Patient...
Read more
IFPMA Artificial Intelligence Principles
Artificial Intelligence (AI) has the potential to bring about positive transformations in science and society, including in healthcare. As a powerful enabler of progress and innovation, AI can increase individual well-being and contribute to the common good. However, while offering tremendous opportunities, relatively new AI technology could also raise concerns relating to potential misuse and inadequate accountability, as well as systemic risks inherent to algorithmic bias and discrimination.
Read more
Diversity and Inclusion in Clinical Trials: Bioethical Perspective and Principles
As IFPMA members, we believe that the knowledge gained from clinical trials should be used to support the development and use of innovative medicines, vaccines and other therapies, in order to develop the right treatment for the right patient.
Read more